⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TEM News
Tempus AI, Inc. Class A Common Stock
Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer Therapy
businesswire.com
TEM
Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034
prnewswire.com
GTBP
LXEO
ANIX
TEM
CTOR
GTBP
LXEO
ANIX
TEM
CTOR
Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution with Upgraded Tyrer-Cuzick Scoring Approach Incorporating Breast Density
businesswire.com
TEM
Kuehn Law Encourages Investors of Tempus AI, Inc. to Contact Law Firm
prnewswire.com
TEM
Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises
prnewswire.com
TEM
CRSP
BNTX
BMY
TEM
CRSP
BNTX
BMY
Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease
prnewswire.com
TEM
Tempus Receives U.S. FDA Special 510(k) Clearance for Updated Tempus Pixel Device
businesswire.com
TEM
Tempus Announces New Study in JCO Precision Oncology Validating PurIST ® Algorithm for Enhanced Therapy Selection in Pancreatic Cancer
businesswire.com
TEM